文献速递乳腺乳腺X线USMR

活检标记物标准化:名称为何重要?

Biopsy Marker Standardization: What's in a Name?
PubMed 文献 · AJR Am J Roentgenol · 2019-04-11

该研究回顾性汇总了一家机构2012年1月至2018年1月遇到的乳腺活检标记物,并补充厂商资料与文献,共识别6家厂商的38种标记物形状,整理出37种钼靶图像并按厂商命名法统一命名,同时总结其特性、陷阱与模仿物,认为外观与命名差异可能导致误判、沟通不畅甚至切除错误病灶,标准化命名临床有用且必要。

要点

  • 乳腺活检标记物有38种形状、来自6家厂商,外观和命名差异可能致误判与沟通错误。
  • 按厂商名称统一命名并配钼靶图像指南,有助于识别标记物及避免切除错误病灶。
  • 需注意标记物模仿物及厂商报告的材质与载体特性(如迁移减少、超声可见性增强、MRI磁敏感差异)。

核心结论

  • 乳腺活检部位标记物外观与命名的变异性可能造成误判、沟通不畅甚至切除错误病灶,全面的命名指南临床有用且标准化是必要的。

研究设计与样本

  • 回顾性综述,纳入2012年1月至2018年1月单家机构遇到的所有乳腺活检标记物(含本院放置及外院放置后转诊者),并补充厂商与文献的绘图、照片及标记物信息,共识别6家厂商的38种标记物形状并整理37种钼靶图像。

关键影像表现/征象

  • 按厂商整理37种标记物的钼靶图像,覆盖不同投照体位。
  • 记录标记物的内在特性、特征、陷阱及模仿物。
  • 厂商报告的标记物材质组成与载体特性包括迁移减少、超声可见性增强及不同程度的MRI磁敏感差异。

临床应用与阅片要点

  • 阅片时按厂商名称统一命名标记物,并对照标准化图像指南识别其形状。
  • 注意识别标记物模仿物及厂商报告的载体特性(迁移、超声可见性、MRI磁敏感差异)对判读的影响。
  • 作者认为标准化命名临床有用且必要,以减少误判、沟通不畅及切除错误病灶。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purposes of this study were to compile mammographic images in various projections showing commercially available breast biopsy site markers and to provide a standardized nomenclature and marker guide to improve physician communication and patient care. MATERIALS AND METHODS. A retrospective review of all breast biopsy markers encountered at one institution was conducted from January 2012 to January 2018. Markers placed at the facility and those placed at outside institutions with the patient subsequently referred to the study institution were included. Additional drawings and photographs and biopsy marker information were compiled from manufacturers and the literature. Intrinsic properties, features, pitfalls, and biopsy marker mimics were recorded from the institution's experience and the literature. RESULTS. Thirty-eight different biopsy marker shapes available from six manufacturers were identified, and mammograms of 37 were compiled and organized by manufacturer. Nomenclature was compiled on the basis of the manufacturer names of each marker. Potential pitfalls and mimics were identified. Manufacturer-reported marker material composition and carrier properties were summarized, including decreased marker migration, enhanced ultrasound visibility, and varying MRI susceptibility. CONCLUSION. Variability in the appearance and nomenclature of breast biopsy site markers may contribute to misinterpretation, miscommunication, and possibly removal of the incorrect lesion. A comprehensive guide to breast biopsy marker nomenclature is clinically useful, and standardization is necessary.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Portnow LH, Thornton CM, Milch HS, et al. Biopsy Marker Standardization: What's in a Name? AJR Am J Roentgenol. 2019. PMID: 30973777. doi:10.2214/AJR.18.20577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。